- Home
- AYTU vs KZIA Comparison
AYTU vs KZIA Comparison
Compare AYTU & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYTU
- KZIA
- Stock Information
- Founded
- AYTU N/A
- KZIA 1994
- Country
- AYTU United States
- KZIA Australia
- Employees
- AYTU N/A
- KZIA N/A
- Industry
- AYTU Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- AYTU Health Care
- KZIA Health Care
- Exchange
- AYTU Nasdaq
- KZIA Nasdaq
- Market Cap
- AYTU 15.0M
- KZIA 12.6M
- IPO Year
- AYTU N/A
- KZIA 1999
- Fundamental
- Price
- AYTU $2.36
- KZIA $0.44
- Analyst Decision
- AYTU
- KZIA Strong Buy
- Analyst Count
- AYTU 0
- KZIA 1
- Target Price
- AYTU N/A
- KZIA $2.00
- AVG Volume (30 Days)
- AYTU 29.8K
- KZIA 1.7M
- Earning Date
- AYTU 11-12-2024
- KZIA 10-15-2024
- Dividend Yield
- AYTU N/A
- KZIA N/A
- EPS Growth
- AYTU N/A
- KZIA N/A
- EPS
- AYTU N/A
- KZIA N/A
- Revenue
- AYTU $81,002,000.00
- KZIA $382.00
- Revenue This Year
- AYTU N/A
- KZIA $4,053,954.00
- Revenue Next Year
- AYTU N/A
- KZIA N/A
- P/E Ratio
- AYTU N/A
- KZIA N/A
- Revenue Growth
- AYTU N/A
- KZIA N/A
- 52 Week Low
- AYTU $2.20
- KZIA $0.19
- 52 Week High
- AYTU $3.50
- KZIA $1.58
- Technical
- Relative Strength Index (RSI)
- AYTU 44.84
- KZIA 62.71
- Support Level
- AYTU $2.26
- KZIA $0.38
- Resistance Level
- AYTU $2.47
- KZIA $0.51
- Average True Range (ATR)
- AYTU 0.15
- KZIA 0.03
- MACD
- AYTU -0.01
- KZIA 0.01
- Stochastic Oscillator
- AYTU 16.10
- KZIA 65.10
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.